Interleukin-10 inhibits autonomous myelopoiesis in patients with myelofibrosis

Eur J Haematol. 2015 Sep;95(3):239-43. doi: 10.1111/ejh.12486. Epub 2015 Jan 7.

Abstract

The spontaneous formation of colony-forming units granulocyte/macrophage (CFU-GM) in semisolid cultures has been shown to be due to the endogenous release of cytokines and/or to the hypersensitivity of cells against growth factors. We have reported that increased autonomous CFU-GM growth is an in vitro characteristic of myelofibrosis (MF) which may reflect aberrant hematopoiesis in vivo. Because of its cytokine synthesis-inhibiting action, we speculated that interleukin-10 (IL-10) may inhibit pathological overproduction of myeloid cells in MF by suppression of autonomous myelopoiesis. In this study, IL-10 significantly inhibited autonomous CFU-GM formation in vitro from peripheral blood mononuclear cells (PB MNC) in 10 of 11 patients with MF tested. In all patients, there was a mean inhibition of 69% ranging from 35% to 100%. Suppression of autonomous CFU-GM formation by IL-10 was dose dependent and reversible by the addition of anti-IL-10 antibodies. Our results indicate that IL-10 is a potentially useful molecule to affect aberrant myelopoiesis in patients with MF.

Keywords: interleukin-10; myelofibrosis; spontaneous CFU-GM.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Colony-Forming Units Assay
  • Dose-Response Relationship, Drug
  • Female
  • Granulocyte-Macrophage Progenitor Cells / drug effects
  • Granulocyte-Macrophage Progenitor Cells / metabolism
  • Humans
  • Interleukin-10 / metabolism*
  • Interleukin-10 / pharmacology
  • Male
  • Middle Aged
  • Myelopoiesis*
  • Primary Myelofibrosis / metabolism*

Substances

  • Interleukin-10